Latest filing published 08 Oct 2024 for X4 Pharmaceuticals, Inc.
Filing timeline
BuySaleInsider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Arthur Taveras: trading record in brief
This profile gathers the share dealings of Arthur Taveras in X4 Pharmaceuticals, Inc, where the filings describe the role as senior executive. In total, 11 filings cover trades dated from 24 March 2021 to 7 October 2024.
Every open-market trade on record is a sale: 6 sales worth €113k. Other entries cover 5 share grants. Since January 2024: no purchases and 3 sales on the market.
The latest filing, published on 8 October 2024, reports an open-market sale of €39k in X4 Pharmaceuticals, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Arthur Taveras
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 230,645 shares0Common StockSEC:0001628280-24-042541:0
- 14,235 shares@ US$0.881815.7% of flowCommon StockSEC:0001628280-24-010281:0
- 787 shares@ US$1.00721.0% of flowCommon StockSEC:0001628280-24-004287:0
- 67,695 shares@ US$0.7363.9% of flowCommon StockSEC:0001628280-23-036755:0
- 230,645 shares0Common StockSEC:0001628280-23-036463:0
- 16,806 shares@ US$0.8418.3% of flowCommon StockSEC:0001628280-23-007721:0
- 928 shares@ US$0.931.1% of flowCommon StockSEC:0001628280-23-003759:0
- 97,000 shares0Common StockSEC:0001628280-22-004499:0
- 928 shares0Common StockSEC:0001628280-22-002507:0
9 of 9 declarations
